While some developers are implementing lessons learned – and launching – their 2nd C>s to market, the majority are hoping the launch strategy for their 1st holds strong, as they navigate through a meteor shower of risky unknowns, firsts, new partnerships, and complexities the average pharma team has never experienced before. To succeed commercially, pharma and biotech need to formulate a launch strategy that engages the right commercial resource early on, rewrites traditional payment models in partnership with payers, and provides an integrated delivery network that scales up seamlessly, end-to-end.
At Reuters Events’ Cell & Gene Therapy USA 2021, you will receive key lessons learned from those who have already achieved lift off. C-suite, commercial strategy, manufacturing and supply, pricing and access experts will provide you with the tools to launch successfully and sustain and scale your cell and gene therapy delivery in to hyperdrive.
Mission Bio is committed to being your trusted partner to help tackle the commercialization challenges facing the industry today and accelerate your therapy development programs. In doing so, Mission Bio’s Ania Wronski, Ph.D. will be hosting a Round Table discussion as part of the curriculum at Reuters CGT USA 2021. Be sure to register for the event and sign up early as spaces are limited!